Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP
Health
Derek Rose

EXPLAINED: Asx drug companies applaud tga s psychedelic ruling | Vintage Vibes

Little Green Pharma plans a clinical trial to evaluate the use of psilocybin to treat depression. (PR HANDOUT IMAGE PHOTO) (AAP)

ASX-listed small-cap drug companies are soaring as two firms announce plans to take advantage of Australia's medical regulator relaxing the rules around two mind-altering drugs.

The Therapeutic Goods Administration on Friday announced it was down-scheduling psilocybin and MDMA, allowing both to dispensed as of July 1 by authorised psychiatrists to treat certain mental health conditions.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.